Home Newsfeeds FDA Reported Monday It Is Requiring Boxed Warning For CAR-T Cancer Therapies

FDA Reported Monday It Is Requiring Boxed Warning For CAR-T Cancer Therapies

https://www.fda.gov/media/175627/download?attachment https://www.fda.gov/media/175626/download?attachment https://www.fda.gov/media/175625/download?attachment https://www.fda.gov/media/175624/download?attachment https://www.fda.gov/media/175622/download?attachment https://www.fda.gov/media/175623/download?attachment

byCharles Gross

January 23, 2024

1 minute read

https://www.fda.gov/media/175627/download?attachment

https://www.fda.gov/media/175626/download?attachment

https://www.fda.gov/media/175625/download?attachment

https://www.fda.gov/media/175624/download?attachment

https://www.fda.gov/media/175622/download?attachment

https://www.fda.gov/media/175623/download?attachment

Oppenheimer Maintains Outperform on CarMax, Lowers Price Target to $75

By Benzinga Newsdesk

December 23, 10:03 AM

Oppenheimer analyst Brian Nagel maintains CarMax (NYSE:KMX) with a Outperform and lowers the price target from $100 to $75.

KMX

Mercury Systems Sees Q3 23 EPS $0.32-$0.42 Vs $0.61 Est.; Q3 23 Revenue $245M-$260M Vs $266.61M Est

By Happy Mohamed

January 31, 5:13 PM

For the third quarter of fiscal 2023, revenues are forecasted to be in the range of $245.0 million to $260.0 million. GAAP net (loss) income for the third quarter is expected to be

MRCY